We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals

108 hedge funds and large institutions have $391M invested in Enanta Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 50 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

94% more capital inflows, than outflows

Capital inflows: $67.8M | Capital outflows: $35M

30% more call options, than puts

Call options by funds: $164K | Put options by funds: $126K

10.82% more ownership

Funds ownership: 95.09% → 105.91% (+11%)

2% more funds holding

Funds holding: 106 → 108 (+2)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

48% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 50

Holders
108
Holders Change
+2
Holders Change %
+1.89%
% of All Funds
1.55%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
15
Increased
26
Reduced
50
Closed
14
Calls
$164​K
Puts
$126​K
Net Calls
+$38​K
Net Calls Change
+$71​K

ENTA Hedge Fund Activity: Q1 2024 in Review

108 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2024, worth a combined $391M — up 108% from $188M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ENTA positions and 14 closed out — a net gain of 1 holder — while 26 added to existing stakes and 50 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $12.6M. The largest seller was Armistice Capital, cutting an estimated $11M.

  • 108 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2024, up from 106 in Q4 2023.
  • Funds reported $391M of Enanta Pharmaceuticals stock for Q1 2024, up 108% quarter-over-quarter.
  • 15 funds opened new Enanta Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +1 holder.
  • The largest Enanta Pharmaceuticals buyer in Q1 2024 was Marshall Wace, an estimated $12.6M added.
  • The largest Enanta Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $11M sold.

Based on aggregated 13F filings for Q1 2024.